Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”

Ann Oncol 2012; 23: 791–800 (doi: 10.1093/annonc/mdr294)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB is the consultant and on the advisory board for Roche and Novartis.